SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir's recent report and forward guidance are sparking heated debate, with some celebrating the company's growth in the AI space while others express concerns about its high valuation. The community is divided between those who see long-term potential and those who anticipate a correction. Discussions also involve CEO Karp's commentary and Michael Burry's short position against the stock.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss the potential impact of recent trial results and earnings, with debates focusing on the future of Elevidys and its potential to replace older treatments. The community is weighing positive revenue beats against concerns about trial data and FDA decisions, with some speculating about a potential buyout. Sentiment is mixed, with bulls emphasizing long-term growth potential and bears pointing to regulatory uncertainty and potential market corrections.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending amidst mixed reactions to recent earnings, with community members debating whether a revenue beat and EPS miss present a buying opportunity or a value trap. Discussions also revolve around the potential impact of a possible easing of rare earth export restrictions by China, balanced against the company's strategic position in domestic uranium and rare earth production. Some traders point to substantial call option activity, while others focus on technical indicators and potential government support for the sector.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amid discussions around Q3 earnings, potential short squeeze, and a possible partnership with Novo Nordisk. Community talking points revolve around the company's growth potential, expansion into new markets like comprehensive testing and international, and revenue acceleration, with some expressing concerns around profitability and volatility. Speculation around partnerships and target prices is also contributing to the heightened interest.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending amid discussions about its correlation with Ethereum's price movements and the broader crypto market. Community members are debating the influence of figures like Tom Lee, while also analyzing institutional ownership and potential impacts from broader market corrections. The stock's volatility and its positioning as an ETH treasury are key talking points.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending amid discussions about its strategic direction and upcoming R2 vehicle launch. The community is focused on the company's potential to compete in the mass market and address existing quality and service concerns. Some are also considering how recent partnerships and fleet orders might impact the company's growth.

Grab Holdings Ltd. engages in the provision of millions of people each day to access its driver- and merchant-partners to order food or groceries, send packages, hail a ride or taxi, pay for online purchases or access services such as lending, insurance, wealth management and telemedicine, all through a single “everyday everything” app. The firm operates in food deliveries and mobility and by TPV in the e-wallets segment of financial services in Southeast Asia. It operates across the deliveries, mobility and digital financial services sectors in eight countries namely: Cambodia, Indonesia, Malaysia, Myanmar, the Philippines, Singapore, Thailand and Vietnam. The company was founded by Anthony Tan Ping Yeow and Tan Hooi Ling in 2012 and is headquartered in Singapore.

Grab Holdings Limited - Ordinary Shares - Class A

Grab Holdings Limited

Grab Holdings ($GRAB) is trending as investors discuss its recent Q3 2025 earnings, which beat revenue estimates. Bullish sentiment is fueled by strong GMV growth, strategic partnerships, and increased call buying activity, with some community members eyeing a potential breakout above $6.50 and a run to $10.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is trending amid discussions about its potential for a significant price increase, with some community members drawing comparisons to ZEC and speculating on a possible "privacy coins season." Community members highlight DASH's limited supply and potential for high gains, with some suggesting it is undervalued. Conversations also mention its utility in regions with high inflation and its potential for use in decentralized finance.

Goodyear Tire & Rubber Co. engages in the development, manufacture, distribution, and sale of tires. It operates through the following geographical segments: Americas, Europe, Middle East, and Africa, and Asia Pacific. The Americas segment is involved in the development, manufacture, distribution, and sale of tires and related products and services in North, Central, and South America. The Europe, Middle East, and Africa segment focuses on the development, manufacture, distribution, and sale of tires for automobiles, trucks, buses, aircraft, motorcycles, earthmoving, mining, and industrial equipment throughout Europe, the Middle East, and Africa. The Asia Pacific segment refers to the development, manufacture, distribution, and sales of tires for automobiles, trucks, buses, aircraft, farm, earthmoving, mining, and industrial equipment throughout the Asia Pacific region. The company was founded by Frank A. Seiberling on August 29, 1898 and is headquartered in Akron, OH.

Goodyear Tire & Rubber Co.

GT is trending due to renewed community focus on its potential undervaluation, highlighted by comparisons of its market cap to sales and analyst price targets. Community members are actively discussing the company's turnaround progress, including debt reduction and savings from the Goodyear Forward plan. Some caution is expressed around tariffs and economic headwinds.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors discuss a potential offering following recent earnings and a new clinical program, while also considering the impact of a new CFO. The community debates management's spending and strategy, as well as the lawsuit against CMS, with some expressing frustration over the stock's performance despite company progress. Bullish investors focus on revenue growth, potential acquisitions, and positive analyst ratings, while bears cite concerns about dilution and management decisions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

June 26, 2025<a target="_blank" rel="noopener noreferrer nofollow" href="https://jaguarhealth.gcs-web.com/node/15251/pdf">PDF Version</a>Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of valueSAN FRANCISCO, CA / <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 26, 2025 / <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue6">Jaguar Health, Inc.</a> (<a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue7">NASDAQ:JAGX</a>) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset."Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation," said Lisa Conte, Jaguar's Founder and CEO. "Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company."Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue8">Canalevia</a>® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company.About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue9">Entheogen Therapeutics Initiative</a> (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.For more information about:Jaguar Health, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buea">https://jaguar.health</a>Napo Pharmaceuticals, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueb">www.napopharma.com</a>Napo Therapeutics, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buec">napotherapeutics.com</a>Magdalena Biosciences, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bued">magdalenabiosciences.com</a>Canalevia-CA1, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buee">canalevia.com</a>Visit the Make Cancer Less Shitty patient advocacy program on <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buef">Bluesky</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueg">X</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueh">Facebook</a> &amp; <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buei">Instagram</a>Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the Company.In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.CONTACT: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:hello@jaguar.health">hello@jaguar.health</a> Jaguar-JAGXSOURCE:&nbsp;Jaguar Health, Inc. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-board-of-directors-authorizes-company-to-include-crypto-1043232">press release</a>

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Others

Investor retail chatter spiked for Jaguar Health Inc. on Wednesday after the company revealed its plan for a $1.5 million registered direct offering priced at-the-market under Nasdaq rules.Jaguar Health shares fell 27.05% to close at $4.26 on Wednesday, before recovering 3.99% in after-hours trading to $4.43.The biopharmaceutical company finalized agreements to exchange 246,306 shares of common stock for $6.09 per share.&nbsp;Jaguar will distribute unregistered warrants in a simultaneous private placement. The exercise price is $5.84 per share, and purchasers can buy up to 492,612 shares.&nbsp;These warrants become exercisable immediately and expire after a fundamental transaction or liquidation event occurs or after 24 months, whichever condition is first met.The offering's closure is scheduled for May 22, subject to standard conditions. H.C. Wainwright &amp; Co. holds exclusive placement agency responsibilities.Jaguar plans to use net proceeds to finance general corporate purposes, such as growth capital funding, working capital maintenance, convertible note repayment, and capital expenditure needs.On Stocktwits, retail sentiment was ‘bullish’ amid a 444% surge in 24-hour message volume.Some retail traders described the offering as a “dip opportunity,” pointing to prior disclosures about share sales through the at-the-market program and suggesting the move had been anticipated since 2022.&nbsp;<stembedurl>https://stocktwits.com/jimiinfinity/message/615411703</stembedurl>Others framed the discounted pricing as a potential entry point, expressing optimism about upcoming news and the company’s trajectory.<stembedurl>https://stocktwits.com/Torobravo_1/message/615384587</stembedurl>The stock has declined 84.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’

Jaguar Health is raising $1.5 million through a registered direct offering and concurrent private warrants placement to support general corporate and growth initiatives.

Equity

Exploring Jaguar Health's Earnings Expectations

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

Why Jaguar Health (JAGX) Stock Is Down 15%

Jaguar Health shares are trading lower by 15.4% during Tuesday's session. The company reported worse-than-expected second-quarter results.
read more...

Why Jaguar Health Stock Is Tanking

Jaguar Health shares are falling Monday after the company announced a 1-for-60 reverse stock split. The company will effect a reverse stock split at an exchange ratio of 1-for-60, on Thursday, in...

Futures Rise, Commodities Soar After Iran's President Dies In Helicopter Crash

Futures Rise, Commodities Soar After Iran's President Dies In Helicopter Crash

 Futures are higher across the board as investors shift their focus from macro to micro, following a...

Peering Into Jaguar Health's Recent Short Interest

12 acciones de salud en movimiento durante la preapertura del 10/04/2024

Acciones al alza
Jaguar Health (NASDAQ:JAGX) avanzaron un 43,99% para establecerse en los 0,13 d lares durante la sesi n del pre-market del mi rcoles.
Adial Pharmaceuticals (NASDAQ:ADIL) ganaron un...

12 titoli sanitari in movimento, pre-market del 10/04/2024

Titoli in rialzo
Il titolo Evoke Pharma (NASDAQ:EVOK) ha osservato un incremento del 41,47% a 0,75 dollari durante la sessione pre-market di mercoled .
Le azioni di Jaguar Health (NASDAQ:JAGX) sono...

This account has been verified as an official JAGX representative.

Verified Account

Jagaur Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health Inc

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

JAGX
Jaguar Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings:

Historical Earnings

Latest JAGX News

JAGXJaguar Health Inc